Contact
/
Home
/
About
Team
Portfolio
Exit History
News
About
Team
Portfolio
Exit History
News
Advent Life Sciences
Advent Life Sciences
Page 5 of 24
<< Start
< Prev
1
2
3
4
5
6
7
8
9
10
Next >
End >>
01.04.2021
Eloxx Pharmaceuticals Acquires Zikani Therapeutics
Press Release
24.03.2021
Aura Biosciences Expands Executive Leadership Team with the Appointment of Mark De Rosch, Ph.D., as Chief Operating Officer
Press Release
22.03.2021
Aura Biosciences Announces Oversubscribed $80 Million Financing
Press Release
17.03.2021
Advent Life Sciences’ founded Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets
Press Release
17.03.2021
Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets
Press Release
12.03.2021
Advent Life Sciences Becomes Latest Partner of One Nucleus
Press Release
02.03.2021
Highlight Therapeutics and Pivotal work together on Melanoma therapy and launch a Phase IIa trial to examine BO-112 efficacy and safety
Press Release
18.02.2021
Advent Life Sciences Announces Close of Two New Funds Totalling $215 million
Press Release
16.02.2021
Centessa Pharmaceuticals Launches with $250 Million Series A Financing and Unveils a New Kind of Pharmaceutical R&D Model
Press Release
25.01.2021
Iterum Therapeutics Announces U.S. FDA Filing Acceptance of New Drug Application for Oral Sulopenem
Press Release
©2022 Advent Life Sciences